重度哮喘问卷的敏感性变化与最小临床重要差异
该研究采用锚定法计算重度哮喘问卷(SAQ)的最小临床重要差异(MCID),发现SAQ的MCID为0.5,SAQ-global的MCID为11,且SAQ对变化敏感,在开始生物制剂治疗4周内可检测到临床显著改善。
要点
- SAQ的MCID为0.5,SAQ-global的MCID为11。
- SAQ在生物制剂治疗4周内可检测到临床显著改善。
- 采用锚定法计算MCID,基于患者感知的差异。
核心结论
- SAQ对变化敏感,其MCID为0.5,SAQ-global的MCID为11。
研究设计与样本
- 本研究为采用锚定法计算MCID的研究,样本量未报告。
主要发现
- SAQ在开始生物制剂治疗4周内可检测到临床显著改善。
- SAQ的MCID为0.5,SAQ-global的MCID为11。
关键数值与推荐
- SAQ的MCID为0.5,SAQ-global的MCID为11。
临床怎么用
- SAQ可用于评估重度哮喘患者健康相关生活质量的变化,MCID有助于判断临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Severe Asthma Questionnaire (SAQ) is sensitive to change and clinically significant improvement was detected within 4 weeks of starting biologic therapy. The MCID of the SAQ is 0.5 and of the SAQ-global is 11. https://bit.ly/3poJqcG The Severe Asthma Questionnaire (SAQ) is a validated measure of the health-related quality of life of people living with severe asthma [1]. The minimal clinically important difference (MCID) of the SAQ has not been calculated. The MCID is useful for representing clinical as opposed to statistical significance. There are two main ways of calculating the MCID. Distribution methods define the MCID in terms of the relationship between the distribution of scores and mean change score. These methods are purely statistical and the relationship and formulae that constitute the MCID is determined by convention. By contrast, the anchor method [2] defines the MCID in terms of an independent anchor or criterion. When the anchor is the patient's perception of a just noticeable difference in their condition, then the anchor method has two advantages over the distribution method. First, the MCID is defined by a criterion and, therefore, has criterion validity rather than being only a convention. Second, the MCID is defined in terms of the patient's perception of treatment, and the patient's perception of their treatment is recognised as being an important outcome for clinical decision-making [2]. In this letter we present the MCID of the SAQ using the anchor method.
引用
- Masoli M, Lanario JW, Hyland ME, et al. The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference. Eur Respir J. 2021. PMID: 33632801. doi:10.1183/13993003.00300-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。